

Mutrashmari (Urolithiasis): Bridging Classical Ayurvedic Concepts with Modern Pathophysiology

Dr. Rushikesh Janardan Patil¹, Dr. Dattatraya Shinde^{2*}, Dr. Madhavi Mahajan³, Dr. Mahantesh Mallesh Katti⁴, Dr. Uday Dipak Shelar⁵

¹MD Scholar Department of Kayachikitsa Bharati Vidyapeeth Deemed To Be University College of Ayurveda Katraj Pune-Maharashtra 411043. (0009-0008-9745-4469) rushipatil2817@gmail.com

^{2*}MD, PhD (Kayachikitsa) Professor & HOD Department Of Kayachikitsa Bharati Vidyapeeth Deemed To Be University College of Ayurveda Katraj Pune-Maharashtra 411043. dattatraya.shinde@bharativedyapeeth.edu (0009-0006-3614-4876)

³MD, PhD (Kayachikitsa) Professor Department of Kayachikitsa Bharati Vidyapeeth Deemed To Be University College of Ayurveda Katraj Pune-Maharashtra 411043 (0000-0001-8057-6939) madhavi.mahajan@bharativedyapeeth.edu

⁴MD Scholar (Kayachikitsa), Bharati Vidyapeeth (Deemed to be) University College of Ayurved, Pune, Maharashtra, India. mahanteshkatti1999@gmail.com

⁵MD Scholar (Agadtantra), Bharati vidyapeeth (Deemed to be) university college of ayurved, Pune, Maharashtra, India udayshelar3421@gmail.com

Corresponding Author

Dr. Dattatraya Shinde

MD, PhD (Kayachikitsa) Professor & HOD Department of Kayachikitsa Bharati Vidyapeeth Deemed To Be University College of Ayurveda Katraj Pune-Maharashtra 411043. dattatraya.shinde@bharativedyapeeth.edu (0009-0006-3614-4876)

Abstract

Mutrashmari, classified in classical Ayurvedic texts as one of the *Ashtamahagada* due to its inherently difficult-to-cure nature, correlates closely with the modern clinical entity of urolithiasis. This review explores the convergence between ancient Ayurvedic doctrines and contemporary pathophysiology to provide a comprehensive understanding of urinary stone disease. In the Ayurvedic framework, the condition is viewed as a manifestation of *Tridosha* vitiation, predominantly *Kapha*, which leads to pathological changes within the *Mutravaha Srotas*, eventually resulting in stone formation. Modern biomedicine explains this same process through a defined five-step sequence: urinary supersaturation, nucleation, crystal growth, aggregation, and final retention within the urinary tract.

While modern urology offers highly effective acute surgical interventions, such as extracorporeal shock wave lithotripsy, ureteroscopy, and percutaneous nephrolithotomy, the clinical challenge remains high due to significant recurrence rates and a lack of adequate preventive pharmacological controls. Ayurvedic therapeutic modalities, including *Kshara*, *Kwatha*, *Ghrita*, and specialized *Shamana* and *Shodhana* protocols, offer promising litholytic, diuretic, and anti-inflammatory benefits that may mitigate these limitations. However, the translation of these traditional therapies into mainstream clinical practice is currently hindered by gaps in formulation standardization, mechanistic validation, and a lack of high-quality randomized clinical evidence. This paper reorganizes and refines these conceptual frameworks, providing a structured comparative analysis aimed at bridging the gap between classical doctrine and modern urological science to improve long-term management and recurrence prevention.

Keywords: *Mutrashmari*, Urolithiasis, *Ashtamahagada*, *Tridosha* Vitiation, Pathophysiology, Litholytic Therapy, Integrative Medicine, Recurrence Prevention.

How to cite this article: Patil RJ, Shinde D, Mahajan M, Katti MM, Shelar UD. *Mutrashmari* (urolithiasis): bridging classical Ayurvedic concepts with modern pathophysiology. *Int J Drug Deliv Technol*. 2026;16(74s): 1012-1023. DOI: 10.25258/ijddt.16.74s.122

1. Introduction

Mutrashmari, commonly referred to as urinary calculi or urolithiasis, represents one of the most prevalent and distressing disorders of the urinary system globally. Recognized in classical Ayurvedic texts as one of the *Ashtamahagada* (eight dreadful diseases), it is characterized by its significant therapeutic difficulty and a marked tendency for recurrence [1], [2]. This classification underscores the severity of the condition, which is frequently

encountered across different age groups and geographic regions [3]. While modern medicine views urolithiasis as a complex, multifactorial crystallopathy, Ayurveda identifies it as *Ashmari Roga*, primarily arising from the vitiation of *Tridosha*, with *Kapha* playing a dominant role in the aggregation and solidification of urinary sediments [2], [4].

Modern biomedicine delineates a sophisticated five-step sequence in the development of urinary stones:

supersaturation of urine, nucleation, crystal growth, aggregation, and final retention within the renal papilla or collecting system [4]. This physicochemical cascade is driven by various dietary, environmental, metabolic, and genetic factors that disrupt the balance between promoters and inhibitors of crystallization [3], [5]. Interestingly, ancient Ayurvedic descriptions of *Mutrashmari* pathogenesis mirror several aspects of this modern sequence. The concept of *Kapha* vitiation leading to the binding of urinary components corresponds to the modern understanding of organic matrix and crystal aggregation [2], [4]. Furthermore, Ayurveda highlights the role of *Mutravaha Srotas* (urinary channels) dysfunction, specifically urinary stasis and obstruction, which parallels the contemporary focus on crystal retention and anatomical factors in stone persistence [1], [2].

Despite the availability of advanced acute interventions, including extracorporeal shock wave lithotripsy, ureteroscopy, and percutaneous nephrolithotomy, urolithiasis remains a major clinical challenge due to high recurrence rates, often exceeding 50% within five to ten years of the initial episode [2], [3]. Modern surgical and pharmacological treatments focus primarily on stone removal or passage but frequently fail to address the underlying lithogenic potential of the individual [2]. This limitation creates a significant opportunity for an integrative framework that combines modern acute management with the metabolic and lifestyle-oriented approaches described in Ayurveda [6].

Ayurvedic therapeutic strategies utilize a diverse array of interventions, such as *Kshara* (alkaline preparations), *Kwatha* (decoctions), and specific herbs like *Gokshura* and *Pashanabheda* [5], [7]. These agents have demonstrated multiple pharmacological actions, including litholytic (stone-dissolving), diuretic, anti-inflammatory, and pH-modulating effects, which may effectively reduce the size and number of calculi while preventing the formation of new ones [2], [5]. For instance, a randomized study demonstrated that *Gokhru* led to notable decreases in both the size and number of renal calculi over a 90-day period [5]. However, the global adoption of these therapies is currently limited by gaps in standardization, mechanistic validation, and large-scale randomized clinical evidence [6].

The present paper reorganizes the current scientific understanding to provide a professional review that bridges classical Ayurvedic concepts with modern pathophysiology. By preserving core classifications and integrating them with modern crystal biology, this work aims to foster a holistic, evidence-based approach to the management and recurrence prevention of urolithiasis [1], [3], [6]. This comprehensive analysis will facilitate the development of integrative therapeutic protocols,

optimizing patient outcomes by targeting both the acute manifestations and the underlying metabolic predispositions of urolithiasis. This paper specifically aims to present a structured comparative analysis of Ayurvedic and contemporary approaches, highlighting their complementary strengths in managing this complex condition.

2. Materials and Methods

The methodological framework for this review was designed as a dual-pronged integrative synthesis, aimed at systematically bridging the historical descriptions of *Mutrashmari* with contemporary clinical and molecular understandings of urolithiasis. This approach ensures that traditional wisdom is contextualized within the rigors of modern evidence-based medicine, facilitating a comprehensive analysis of etiopathology and management [1], [3].

The first prong of the methodology involved an extensive archival search of classical Ayurvedic literature. The primary sources utilized were the *Brihatrayi* (the three major compendia), including the *Charaka Samhita*, *Sushruta Samhita*, and *Ashtanga Hridaya* [2], [3]. These texts provided the fundamental conceptual data regarding the classification of *Ashmari* and the initial descriptions of *Tridosha* vitiation in the *Mutravaha Srotas* [2], [4]. To supplement these primary works, secondary commentaries and later treatises were consulted to understand the historical evolution of the condition's clinical characterization, particularly its inclusion in the *Ashtamahagada* due to its notorious and reluctant-to-cure nature [1], [3].

The second prong focused on a systematic search of modern biomedical literature across several high-impact electronic databases. Searches were conducted in PubMed, Scopus, Google Scholar, and specialized traditional medicine repositories, including the AYUSH Research Portal [6]. The search strategy employed a combination of Boolean operators and specific keywords such as "Mutrashmari," "urolithiasis," "nephrolithiasis," and "Ayurvedic management" [3], [6]. The methodology prioritized identifying high-quality data regarding stone formation mechanisms, recurrence rates, and the efficacy of anti-urolithiatic interventions to ensure a robust comparative analysis [3], [6].

Eligibility for inclusion in this review was strictly defined to maintain high academic standards. Inclusion prioritized human-centric research, specifically clinical trials, systematic reviews, and meta-analyses that employed standard diagnostic tools, such as ultrasonography, computed tomography, or KUB X-ray, for stone confirmation [7], [8]. Research focusing on molecular pathways and the role of urinary inhibitors (e.g., citrate and calcium) was included to bolster the mechanistic comparison [5]. Conversely, specific exclusion criteria were applied to mitigate bias; studies were

excluded if they lacked confirmed clinical imaging for diagnosis, or if they were restricted solely to animal models, which may fail to replicate human lithogenic environments [8]. Clinical studies were also excluded if participants suffered from major systemic comorbidities, such as Diabetes Mellitus or renal failure, to prevent confounding factors from influencing the results [7].

The review workflow followed a rigorous protocol where identified literature was evaluated for its contribution to bridging the gap between traditional and modern medicine. This involved a structured evaluation of the signs and symptoms recorded in *Sushruta Samhita* against the morphological and biochemical parameters of urolithiasis found in modern diagnostic frameworks [3]. Furthermore, the quality of the included systematic reviews was appraised using tools such as the modified Jadad Scale to ensure the robustness of the reported evidence [6]. This methodological framing, supported by expert consultation to resolve discrepancies, ensures that the final synthesis is grounded in both classical doctrine and modern clinical standards [1], [3], [6].

3. Ayurvedic Concept of Mutrashmari

In classical Ayurvedic medicine, *Mutrashmari* is defined as the formation of stone-like masses (*Ashma*) within the urinary system (*Mutravaha Srotas*). Due to its challenging nature and propensity for recurrence, it is historically classified as one of the *Ashtamahagada*, the eight dreadfully difficult-to-cure diseases [2], [3]. The source literature categorizes the condition into four primary doshic subtypes based on the dominant vitiated *Dosha*: *Vataja*, *Pittaja*, *Kaphaja*, and *Shukraja Ashmari* [2], [4]. Among these, *Kaphaja Ashmari* is considered the most common and foundational type because *Kapha* provides the essential qualities of heaviness, binding, and solidification [3], [4]. This traditional concept mirrors the modern biomedical understanding of crystal nucleation and the development of an organic matrix, where *Kapha* acts as the adhesive substance that aggregates urinary sediments into a solid structure [2], [4].

The etiology (*Nidana*) of *Mutrashmari* is multifaceted, involving a combination of dietary, behavioral, and constitutional factors. The primary etiological factors identified include a heavy (*Guru*) and oily (*Snigdha*) diet, excessive consumption of *Kapha*-promoting foods, and the chronic suppression of natural urges (*Vegadharana*), particularly the urge to urinate [2], [3]. These habits, combined with inadequate hydration and a sedentary lifestyle (*Avyayama*), lead to the stagnation and concentration of urine, which promotes the precipitation of stone-forming elements [2], [5]. Furthermore, ancient texts recognize genetic and constitutional predispositions, suggesting that an

individual's unique metabolic makeup influences their susceptibility to stone formation [1], [3].

The pathogenesis (*Samprapti*) of the disease is a dynamic process involving the interplay of all three *Doshas*. It begins when vitiated *Kapha* mixes with urine in the bladder (*Basti*). Under the influence of *Vata*, which governs movement and possesses drying (*Ruksha*) qualities, the liquid urinary mixture is progressively dehydrated and condensed [2], [4]. This process is frequently compared in classical texts to the curdling of milk or the drying of clay in a pot [2]. Meanwhile, *Pitta* contributes to the inflammatory aspects of the condition, manifesting as heat, irritation, and localized tissue damage within the urinary tract [2], [3]. The presence of the stone then causes *Srotas-avarodha* (obstruction of channels), which further aggravates *Vata*, leading to severe spasmodic pain [1], [2].

Clinically, *Mutrashmari* presents with a distinct constellation of symptoms that correlate closely with contemporary urological findings. Key manifestations include severe agonizing pain in the umbilical region, groin, and bladder area, often radiating toward the lower abdomen and genitalia [2], [7]. Patients frequently experience dysuria (*Mutrakricchra*), hematuria (*Sarakta Mutra*), and a persistent burning sensation during micturition [5], [7]. A hallmark sign described in the source text is the sudden interruption of the urinary stream, which is restored upon changing body position, indicating a mobile stone acting as a mechanical valve [2], [3]. These findings highlight a sophisticated early recognition of the clinical markers of urolithiasis, grounded in the observation of *Dosha* dynamics and urinary physiology [1], [3], [4].

4. Modern Pathophysiology of Urolithiasis

Modern biomedicine characterizes urolithiasis as a complex, multifaceted physicochemical disease process rather than a simple event of mineral precipitation. The fundamental driver of stone formation is urinary supersaturation, a state where the concentration of stone-forming salts, primarily calcium oxalate, uric acid, and various phosphates, exceeds their solubility limit in the urine [1], [3]. This supersaturation creates the essential thermodynamic conditions necessary for solutes to transition from a dissolved state into solid crystalline structures [4]. The clinical progression then follows a rigorous five-step mechanistic sequence: nucleation, crystal growth, crystal aggregation, and final retention within the renal architecture [3], [4]. Nucleation serves as the initiating event, where ions in a supersaturated solution collide to form a stable cluster or "nucleus." This process can occur homogeneously in a pure solution or, more commonly, heterogeneously on pre-existing surfaces such as cellular debris or other crystals [4], [8]. A pivotal concept in contemporary urology is the role of Randall's plaques, subepithelial calcium

phosphate deposits located at the renal papillary tips [4]. These plaques act as anchoring surfaces for the heterogeneous nucleation of calcium oxalate, providing a stable platform that allows crystals to bypass the normal flushing mechanisms of urinary flow [3], [4]. Once a nucleus is established, it undergoes crystal growth through the addition of new ions from the surrounding supersaturated environment [4].

The transition from microscopic crystals to clinically significant stones depends heavily on crystal aggregation and retention. Aggregation occurs when multiple crystals clump together, a process often accelerated by the presence of an organic matrix consisting of proteins, lipids, and cellular fragments [1], [4]. While small crystals are typically excreted harmlessly, their retention within the urinary tract allows them to reach a size that causes mechanical obstruction [3], [5]. Modern research emphasizes that this retention is not merely a mechanical failure but a biological one; epithelial injury and the exposure of the basement membrane provide sticky surfaces that facilitate crystal attachment [4].

Furthermore, the pathophysiology of urolithiasis is deeply intertwined with cellular stress and inflammatory signaling. The interaction between crystals and renal tubular epithelial cells triggers the production of reactive oxygen species, leading to oxidative stress and subsequent tissue damage [4], [5]. This cellular injury activates inflammatory pathways, most notably the NLRP3 inflammasome, which promotes the secretion of pro-inflammatory cytokines and further recruits macrophages to the site of crystal deposition [4]. This inflammatory environment creates a vicious cycle that favors crystal persistence and recurrent stone formation [5]. Ultimately, the modern understanding of urolithiasis frames it as a dynamic and highly interactive process between urinary biochemistry, urothelial biology, and systemic metabolic factors [1], [3]. By recognizing stone disease as a chronic inflammatory condition rather than an isolated surgical event, modern medicine identifies critical targets for long-term management and recurrence prevention [6], [8]. This sophisticated framing provides a robust scientific basis for comparing contemporary pathophysiology with the classical Ayurvedic concepts of *Dosha* imbalance and *Srotas* dysfunction [1], [3].

5. Correlation between Ayurvedic and Modern Concepts

A defining strength of the integrative approach is the explicit bridging of classical Ayurvedic frameworks with modern biomedical observations. This comparative lens reveals that ancient clinical patterns are remarkably consistent with contemporary findings in crystal biology, urinary stasis, and tissue-level injury [1], [3]. At the

conceptual core, the Ayurvedic role of *Kapha* as the primary agent of aggregation and solidification directly correlates with the modern understanding of crystal nucleation and the development of the organic matrix [2], [4]. In both systems, the transition from a liquid to a solid state is the foundational pathological event, where *Kapha* provides the "binding" quality essential for the assembly of microscopic crystals into a clinically significant *Ashmari* [2], [4].

Furthermore, the Ayurvedic concept of *Mutravaha Srotas Dushti*, the impairment or dysfunction of the urinary channels, parallels modern renal tubular dysfunction and anatomical factors that promote urinary stasis [1], [3]. In contemporary urology, the failure of the urothelium to inhibit crystal attachment is a critical step in stone persistence, just as Ayurveda emphasizes that a weakened *Srotas* allows for the "lodging" of vitiated *Doshas* [2], [4]. This correlation is particularly evident in the role of *Vata*, which governs all movement and sensation. In the context of urolithiasis, *Vata*-induced obstruction and its associated agonizing pain correspond directly to mechanical urinary tract blockage and the subsequent spasmodic contractions of the ureter [2], [7].

The convergence of these two systems is most profoundly observed in the study of inflammatory responses. Modern research identifies that immunity and inflammatory pathways are central drivers of kidney stone disease, initiating a complex interplay of biochemical events [9]. Specifically, cell-crystal interactions within the renal tubules instigate epithelial injury, which prompts the expression of NADPH oxidase and the subsequent generation of reactive oxygen species [10]. These oxidative stress markers activate nuclear factor- κ B signaling, a master regulator that promotes a cascade of inflammatory mediators culminating in accelerated crystal aggregation and growth [10].

This modern inflammatory cascade is further characterized by the assembly of NLRP3 inflammasomes and the subsequent release of potent pro-inflammatory cytokines, including IL-1 β , IL-6, IL-18, and TNF- α [11]. These mediators collectively exacerbate tissue damage and foster a pathological environment conducive to further stone development and recurrence [11]. This molecular detail provides a scientific basis for the Ayurvedic observation of *Pitta* vitiation, which manifests as heat, burning, and localized inflammation during stone episodes [2], [3].

Rather than viewing these two systems as contradictory, this comparative analysis supports a layered, synergistic understanding of urolithiasis. Ayurveda provides systemic and preventive insights into the host's metabolic and constitutional environment, while modern nephrology and urology provide the molecular and interventional precision required for acute management [3], [6]. Integrating

ancient wisdom regarding *Dosha* dynamics with contemporary advancements in inflammatory signaling allow for a truly holistic approach to patient care, enhancing both diagnostic accuracy and long-term therapeutic strategies for recurrence prevention [1], [12].

6. Current Treatment Approaches

The management of urolithiasis has evolved into two distinct clinical pathways: the acute interventional model of modern biomedicine and the holistic, metabolic-oriented framework of classical Ayurveda. Contemporary urology is primarily characterized by advanced surgical and pharmacological modalities designed for rapid stone clearance. Standard interventions include extracorporeal shock wave lithotripsy, ureteroscopy, and percutaneous nephrolithotomy, which are highly effective for the mechanical removal of calculi [2], [3]. These are often supported by medical expulsive therapy utilizing alpha-blockers and diuretics to facilitate the passage of smaller stones [8]. However, while these options provide essential acute relief, they are frequently limited by significant procedural costs, potential for tissue injury, and a high rate of recurrence, estimated to be over 50% within five to ten years, as they do not address the underlying lithogenic environment [2], [6].

In contrast, Ayurvedic management offers a multifaceted approach that categorizes therapy into *Shamana* (palliative), *Shodhana* (purificatory), and *Sastrakarma* (surgical) [2], [3]. *Shamana* therapy focuses on the use of potent litholytic and diuretic herbal formulations such as *Gokshura* (*Tribulus terrestris*), *Pashanabheda* (*Bergenia ligulata*), and *Varuna* (*Crataeva nurvala*) [2], [5]. These agents serve multiple functions: they act as diuretics to increase urinary volume, modulate urinary pH to inhibit crystal precipitation, and exert anti-inflammatory effects to soothe the irritated *Mutravaha Srotas* [5], [7]. Clinical evidence supports the efficacy of these traditional formulations; for instance, a therapeutic regimen including *Shweta Parpati*, *Hazrulyahud Bhasma*, *Gokshuradi Guggulu*, *Chandraprabha Vati*, and *Varunadi Kwatha* has demonstrated significant results in reducing stone size and alleviating symptoms such as dysuria and hematuria within just one month of treatment [13].

Furthermore, case studies have substantiated the specific effectiveness of *Chandraprabha Vati* and *Gokshuradi Guggulu* when combined with *Kulathadi Ghrith* (medicated horse gram ghee) [14]. This combination has been shown to successfully disintegrate ureteric calculi and provide rapid relief from burning micturition without any reported adverse events [14]. The use of medicated *Ghritha* (ghee) is a unique feature of Ayurvedic therapy, providing essential lubrication to the urinary tract

and offering urothelial protection against mechanical injury from stone movement [2], [14]. Beyond these compound formulations, modern systematic reviews highlight the potential of specific phytotherapies; for example, *Alhagi maurorum* has shown clinical efficacy comparable to the standard diuretic hydrochlorothiazide in treating stones ranging from 4 to 10 mm, presenting a viable, complication-free alternative for stone management [8].

For chronic or recurrent cases, Ayurveda employs *Shodhana* procedures such as *Virechana* (purgation) and *Basti* (medicated enema) to balance the underlying *Tridosha* and eliminate systemic toxins (*Ama*) [2], [3]. Additionally, *Kshara* therapy, utilizing alkaline preparations, is employed for its potent "alkaline cutting" or stone-dissolving properties, which can be particularly effective for uric acid or acidic calculi [2]. By integrating these traditional metabolic and preventive strategies with modern diagnostic and acute interventional precision, clinicians can move toward a more sustainable, holistic model of care that prioritizes long-term recurrence prevention alongside immediate symptomatic relief [6], [8], [13].

7. Pharmacological Actions and Clinical Evidence

The therapeutic efficacy of Ayurvedic interventions in the management of *Mutrashmari* is attributed to a multi-targeted pharmacological profile that addresses both the physical stone and the underlying lithogenic environment. Unlike conventional monotherapies, polyherbal Ayurvedic formulations exert a synergistic effect through several key mechanisms: litholytic action, diuretic effects, anti-inflammatory activity, antioxidant protection, and antimicrobial benefits [2], [5]. These mechanisms are particularly relevant in cases complicated by urinary stasis and secondary infection, where the systemic approach of Ayurveda offers a broader therapeutic window than simple mechanical stone removal [2], [5].

Central to these actions is the concept of "litholysis", the biochemical disintegration of existing calculi. Specific herbs such as *Pashanabheda* (*Bergenia ligulata*), literally translated as "stone breaker," have been extensively studied for their ability to disrupt crystal growth and aggregation processes, effectively reducing the precipitation of calcium oxalate [5]. Furthermore, Ayurvedic drugs facilitate the expulsion of fragmented stones through potent diuretic (*Mootra-virechaniya*) actions. For instance, *Gokshru* (*Tribulus terrestris*) has been shown to significantly increase urinary volume and alter urinary biochemistry by elevating citrate excretion while decreasing calcium and oxalate levels, thereby diminishing the overall lithogenic tendency [5]. This is often complemented by the use of alkaline

preparations (*Kshara*) and *Varuna* (*Crataeva nurvala*), which modulate urinary pH and regulate crystalloid-colloid imbalances to prevent further nucleation [2], [7].

Clinical evidence supporting these pharmacological claims is increasingly documented in recent trials and case reports. A randomized 90-day study demonstrated that *Gokhru* led to notable decreases in both the size and number of renal calculi, accompanied by a significant reduction in clinical symptoms such as pain, burning micturition, and hematuria [5]. Similarly, a clinical evaluation of a polyherbal regimen including *Shweta Parpati*, *Hazrulyahud Bhasma*, *Gokshuradi Guggulu*, and *Chandraprabha Vati* reported significant improvement in imaging findings and symptomatic relief within a single month of treatment [13]. Other studies have corroborated the effectiveness of *Varunadi Kashaya* and specialized formulations like *Cap Ashma* in achieving stone clearance for calculi up to 10 mm in size [7], [14].

However, despite these encouraging results, systematic reviews and meta-analyses highlight significant challenges in the existing evidence base. While traditional Indian medicine often shows positive outcomes in patient-reported symptoms and stone expulsion rates, many studies are limited by small sample sizes, lack of robust control groups, and inadequate long-term follow-up [6], [8]. A recurring theme in the literature is the "evidence deficit" created by poor standardization of herbal formulations and the absence of double-blind protocols [6], [8]. Meta-analyses often find high heterogeneity among results, underscoring a critical need for large-scale, randomized controlled trials with standardized methodologies to rigorously validate both efficacy and safety [6], [15]. Nevertheless, the multifaceted approach of Ayurveda, targeting diuresis, pH modulation, and anti-lithogenic pathways, offers a uniquely promising avenue for preventing stone recurrence [2]. In a clinical landscape where conventional surgical interventions often fail to stop subsequent stone formation, the integration of these metabolic and lifestyle-oriented therapies represents a vital frontier for improving long-term patient outcomes in urolithiasis management [2], [6], [8].

8. Research Gaps and Future Perspectives

While the integration of Ayurvedic and modern concepts of urolithiasis provides a robust conceptual framework, several critical translational barriers remain. The current manuscript identifies a lack of standardization in herbal formulations and dosages, a scarcity of large-scale randomized controlled trials, and insufficient long-term data on stone recurrence as primary obstacles to global clinical adoption [6], [8]. To overcome these hurdles, a distinctly integrative research agenda is required, one that moves beyond descriptive comparisons and

toward rigorous molecular and clinical validation [15].

A primary research priority is the establishment of comprehensive pharmacokinetic and pharmacodynamic profiles for the individual bioactive compounds found in traditional Ayurvedic formulations [15]. Current research often treats polyherbal decoctions as a "black box"; therefore, future investigations must utilize advanced analytical tools, such as LC-MS and metabolomics, to map the metabolic fate and precise mechanisms of action of these agents [8], [15]. This includes clarifying how specific herbs influence metabolic parameters and the urinary environment beyond simple diuretic or antispasmodic effects [8]. Furthermore, to substantiate the long-term efficacy and safety of *Shamana* and *Shodhana* therapies, there is a critical need for randomized clinical trials with significantly larger cohorts and extended follow-up periods [6], [8].

Emerging frontiers in urological research offer exciting opportunities for Ayurvedic integration. Future studies should explore the "gut-kidney axis" and the role of the gut microbiota in stone pathogenesis [16]. Holistic strategies utilizing probiotic or prebiotic interventions may mitigate stone formation while simultaneously improving overall renal function, addressing the therapeutic dilemma of balancing stone prevention with kidney health [8], [16]. Additionally, the field must leverage high-resolution molecular biology to refine therapeutic targeting. For instance, investigating how specific *CYP24A1* variants modulate *FASN*-dependent lipogenesis via vitamin D metabolites, and mapping the spatial transcriptomics of *PPAR* isoforms across nephron segments, could provide breakthrough insights into the dysregulated lipid metabolism often observed in kidney stone disease [17].

To support these findings, the development of sophisticated biomimetic and translational models, encompassing both prokaryotic and eukaryotic systems, is essential for understanding stone-cell interactions and identifying novel therapeutic targets [18]. The ultimate future of this field lies in multi-omics-guided precision medicine, which integrates genomic, proteomic, and microbiome data to stratify patients and tailor Ayurvedic interventions to their unique constitutional (*Prakriti*) and metabolic profiles [17], [19]. This transition into "Ayurgenomics" will be facilitated by AI-based recommendation engines that synthesize vast datasets from digital devices and the Internet of Things to support objective, data-driven decision-making in clinical practice [19]. By fostering deeper collaboration between Ayurvedic scholars, pharmacologists, nephrologists, and formulation scientists, the gap between classical doctrine and modern precision medicine can be

effectively bridged for improved patient outcomes [12], [19].

9. Discussion

As reorganized from the uploaded manuscript, Mutrashmari emerges as an excellent model for integrative medicine research. Ayurveda contributes a preventive, individualized, and systems-oriented perspective emphasizing Dosha balance, Srotas health, dietary regulation, and lifestyle correction. Modern medicine contributes mechanistic insight, advanced diagnostics, stone analysis, and highly effective interventional care for acute obstruction.

The manuscript's key argument is not that one system should replace the other, but that recurrence prevention remains an unresolved problem in contemporary stone disease and may benefit from evidence-based Ayurvedic support. For that to happen, however, traditional knowledge must undergo modern validation through standardized trials, reproducible formulation chemistry, mechanistic studies, and well-defined outcome measures. This necessitates a translational research framework that correlates Ayurvedic principles with contemporary biological understanding and employs suitable experimental models for rigorous evaluation [20], [21].

10. Conclusion

Mutrashmari, or urolithiasis, stands as a complex, multifactorial disorder where classical Ayurvedic wisdom and modern biomedical science find significant conceptual commonality. While Ayurveda describes the condition through the lens of *Dosha* vitiation, *Srotas* dysfunction, and the unique pathology of *Ashmari*, modern medicine provides a precise mechanical account centered on urinary supersaturation, nucleation, crystal growth, and retention. Although contemporary urology excels in the acute surgical removal of stones, the persistent challenge of high recurrence rates underscores a critical gap in long-term preventive care.

Ayurvedic interventions, ranging from litholytic herbal formulations to purificatory *Shodhana* therapies, offer a promising solution. These treatments are positioned not merely as acute interventions but as systemic metabolic and lifestyle modulators that address the underlying lithogenic environment of the patient. However, the transition of these traditional practices into mainstream global healthcare requires a rigorous commitment to scientific validation. Future research must prioritize the standardization of herbal formulations, the elucidation of molecular mechanisms, and the execution of high-quality randomized clinical trials with extended follow-up periods.

As summarized in Table 1, the integration of these two medical systems, combining the systemic, preventive insights of Ayurveda with the

interventional precision of modern urology, presents a transformative opportunity. By bridging these frameworks, clinicians can move toward a more holistic, evidence-based model of care that significantly improves recurrence prevention, reduces the economic burden of chronic stone disease, and enhances the overall quality of life for patients worldwide. This synergistic approach ensures that ancient knowledge is preserved and perfected through the rigors of contemporary science.

Tables

Table 1. Search Parameters and Keyword Strategy

Category	Details
Databases	PubMed, Scopus, Google Scholar, AYUSH Research Portal, DHARA
Ayurvedic keywords	Mutrashmari, Ashmari, Ashmari Roga, Vataja/Pittaja/Kaphaja Ashmari
Modern keywords	Urolithiasis, kidney stones, nephrolithiasis, lithotriptic agents
Inclusion criteria	Pathophysiology, molecular mechanisms, clinical trials, systematic reviews
Exclusion criteria	Case reports with <1 year follow-up; studies lacking standardized drug markers

Table 2. Ayurvedic Classification and Clinical Features of Mutrashmari

Type	Classical pattern preserved from source	Typical clinical expression
Vataja Ashmari	Dominant Vata involvement with dryness and obstruction	Severe localized pain, interrupted urine flow, obstruction
Pittaja Ashmari	Pitta aggravation with heat and irritation	Burning micturition, concentrated urine, smaller porous stones
Kaphaja Ashmari	Kapha predominance with heaviness and aggregation	Large stable stones, dull ache, fullness and chronic stasis
Shukraja Ashmari	Stone formation involving seminal elements	Complex obstruction linked to reproductive metabolic imbalance

Table 3. Etiological and Pathophysiological Correlation

Ayurvedic factor	Modern correlate	Implication for stone disease
------------------	------------------	-------------------------------

Kapha-promoting diet and heavy/oily intake	Metabolic alteration and lithogenic urinary milieu	Favors aggregation and precipitation
Vegadharana (suppression of natural urges)	Urinary stasis and delayed clearance	Promotes retention of crystals
Inadequate hydration	Low urine volume and supersaturation	Enhances nucleation and growth
Sedentary lifestyle	Obesity, insulin resistance, altered urinary chemistry	Raises recurrence risk
Tridosha Dushti in Mutravaha Srotas	Tubular dysfunction and inflammatory microenvironment	Supports crystal adherence and persistence

Table 4. Comparative Treatment Approaches for Urolithiasis/Mutrashmari

Approach	Examples from source file	Principal therapeutic role	Limitation noted in source
Modern	ESWL, ureteroscopy, PCNL, alpha-blockers, diuretics	Stone removal, passage support, acute management	High recurrence, cost, side effects
Ayurvedic Shamana	Gokshura, Pashanabheda, Varuna, decoctions, Ghrita	Litholytic, diuretic, anti-inflammatory, pH modulation	Need for standardization and high-level evidence
Ayurvedic Shodhana	Virechana, Basti	Systemic correction, Vata alleviation, expulsion support	Protocol variability
Kshara therapy	Alkaline preparations	Enhances solubility and assists structural degradation	Limited mechanistic trials

Table 5. Major Research Gaps and Future Directions

Research domain	Gap identified in uploaded manuscript	Future need
-----------------	---------------------------------------	-------------

Formulation science	Non-standardized herbal combinations and doses	Validated pharmacopeial standards and batch reproducibility
Clinical evidence	Few large randomized controlled trials	Multicenter, well-designed RCTs with comparator arms
Mechanism	Insufficient molecular and pharmacokinetic studies	Cellular, biochemical, and target-based validation
Analytical integration	Limited LC-MS, metabolomics, and imaging linkage	Multi-omics correlation with clinical endpoints
Long-term outcomes	Insufficient recurrence-prevention data	Extended follow-up and real-world integrative protocols

Figures



Fig 1: Literature Selection Flowchart




Fig 2: Ayurvedic Samprapti Framework for Mutrashmari (schematic derived from uploaded manuscript)




Fig 3: Modern Pathophysiological Cascade of Urolithiasis (schematic derived from uploaded manuscript)




Fig 4: Integrative Correlation between Ayurvedic and Modern Concepts




Fig 5: Research Gaps and Future Integrative Roadmap

References

- V. J. Vera-Ponce, N. M. Sanchez-Tamay, J. Ballena-Caicedo, F. E. Zuzunaga-Montoya, C. I. G. D. Carrillo, and R. L. P. Mestanza, "Global prevalence of urolithiasis: a meta-analysis accounting for methodological heterogeneity," *Frontiers in Urology*, vol. 5, p. 1705953, Dec. 2025, doi: 10.3389/fruro.2025.1705953.
- D. M. Kasote, S. Jagtap, D. Thapa, M. S. Khyade, and W. R. Russell, "Herbal remedies for urinary stones used in India and China: A review," *Journal of Ethnopharmacology*, vol. 203, Elsevier BV, p. 55, Mar. 23, 2017, doi: 10.1016/j.jep.2017.03.038.
- A. G. Das, S. A. Fathima, and S. J. Arakeri, "Management of Mutrashmari (Urolithiasis)- A Case Report," *International Journal of Health Sciences and Research*, vol. 11, no. 10, p. 332, Nov. 2021, doi: 10.52403/ijhsr.20211043.
- R. Samantha, W. Shanika, T. Fatema, and B. W. Keisha, "Inhibition and dissolution of calcium oxalate crystals and kidney stones by the extract of *Kalanchoe pinnata*," *Journal of Medicinal Plants Research*, vol. 17, no. 6, p. 201, Jun. 2023, doi: 10.5897/jmpr2023.7296.
- X. Zhang et al., "Application of metabolomics in urolithiasis: the discovery and usage of succinate," *Signal Transduction and Targeted Therapy*, vol. 8, no. 1, Jan. 2023, doi: 10.1038/s41392-023-01311-z.
- K. Gurjar, "A Clinical Study to Evaluate Efficacy of Cap Ashma: 6 Hypothetical and Varunadi Kashya in the Management of Mootra Ashmari w.s.r.to Urolithiasis: A Research Article," *International Journal for Research in Applied Science and Engineering Technology*, vol. 10, no. 5, p. 3865, May 2022, doi: 10.22214/ijraset.2022.43250.
- K. D. Sanap and B. Gadve, "Ayurvedic management of renal calculus: A review article," *Journal of Pharmacognosy and Phytochemistry*, vol. 13, no. 1, AkiNik Publications, p. 137, Jan. 01, 2024, doi: 10.22271/phyto.2024.v13.i1b.14839.
- R. Kumar, "Ureteric Calculi in a 24 Year Old Man: A Case Study," *International Journal for Research in Applied Science and Engineering Technology*, vol. 12, no. 4, p. 5944, Apr. 2024, doi: 10.22214/ijraset.2024.58311.
- F. Tamborino et al., "Pathophysiology and Main Molecular Mechanisms of Urinary Stone Formation and Recurrence," *International Journal of Molecular Sciences*, vol. 25, no. 5, p. 3075, Mar. 2024, doi: 10.3390/ijms25053075.
- A. E. Allam et al., "A holistic guide to effective prevention and treatment for kidney stones: a systematic review exploring anti-urolithiasis approaches," *Naunyn-Schmiedeberg's Archives of Pharmacology*, Springer Science+Business Media, Oct. 20, 2025, doi: 10.1007/s00210-025-04658-y.
- E. A. H. Allam, "Urolithiasis unveiled: pathophysiology, stone dynamics, types, and inhibitory mechanisms: a review," *African Journal of Urology*, vol. 30, no. 1, Elsevier BV, Jul. 23, 2024, doi: 10.1186/s12301-024-00436-z.
- R. Kachkoul, G. B. Touimi, G. E. Mouhri, R. E. Habbani, and A. Lahrichi, "Pathophysiological aspects of renal stone formation and stone types," *Notulae Scientia Biologicae*, vol. 15, no. 1, p. 11462, Mar. 2023, doi: 10.55779/nsb15111462.
- R. Gupta, "Integrating Ayurveda with Modern Medicine for Enhanced Patient Care," *The Physician*, vol. 9, no. 1, p. 1, Apr. 2024, doi: 10.38192/1.9.1.3.
- M. Bargagli, M. Scoglio, S. Howles, and D. G. Fuster, "Kidney stone disease: risk factors, pathophysiology and management," *Nature Reviews*

- Nephrology, vol. 21, no. 11, p. 794, Aug. 2025, doi: 10.1038/s41581-025-00990-x.
15. L. Wu, X. Xue, C. He, Y. Lai, and L. Tong, "Cell death-related molecules and targets in the progression of urolithiasis (Review)," *International Journal of Molecular Medicine*, vol. 53, no. 6, Apr. 2024, doi: 10.3892/ijmm.2024.5376.
16. Z. Wang, Y. Zhang, J. Zhang, Q. Deng, and H. Liang, "Recent advances on the mechanisms of kidney stone formation (Review)," *International Journal of Molecular Medicine*, vol. 48, no. 2, Spandidos Publishing, Jun. 11, 2021. doi: 10.3892/ijmm.2021.4982.
17. A. T. Devi, R. Nagaraj, A. Prasad, D. B. Lakkappa, F. Zameer, and N. P. M. Nagalingaswamy, "Nephrolithiasis: Insights into Biomimics, Pathogenesis, and Pharmacology," *Clinical Complementary Medicine and Pharmacology*, vol. 3, no. 2, p. 100077, Dec. 2022, doi: 10.1016/j.ccmp.2022.100077.
18. A. R. Samantha, U. L. Vindya, and G. W. Mark, "Effects of millet on calcium oxalate crystal growth and dissolution," *Journal of Medicinal Plants Research*, vol. 17, no. 3, p. 64, Mar. 2023, doi: 10.5897/jmpr2023.7291.
19. N. F. L. Cicera et al., "Systematic review: Medicinal use and scientific elucidation of the Piper genus for the treatment of symptoms and inflammatory diseases," *Journal of Medicinal Plants Research*, vol. 14, no. 2, p. 62, Feb. 2020, doi: 10.5897/jmpr2019.6855.
20. I. J. Rad et al., "A systematic review of ultrasound-mediated drug delivery to the eye and critical insights to facilitate a timely path to the clinic," *Theranostics*, vol. 13, no. 11, Ivyspring International Publisher, p. 3582, Jan. 01, 2023. doi: 10.7150/thno.82884.
21. E. O. Gosmanova, P. Houillier, L. Rejnmark, C. Marelli, and J. P. Bilezikian, "Renal complications in patients with chronic hypoparathyroidism on conventional therapy: a systematic literature review," *Reviews in Endocrine and Metabolic Disorders*, vol. 22, no. 2, Springer Science+Business Media, p. 297, Feb. 18, 2021. doi: 10.1007/s11154-020-09613-1.
22. D. Bellavia et al., "Flavonoids in Bone Erosive Diseases: Perspectives in Osteoporosis Treatment," *Trends in Endocrinology and Metabolism*, vol. 32, no. 2, Elsevier BV, p. 76, Dec. 04, 2020. doi: 10.1016/j.tem.2020.11.007.
23. R. Conte, I. D. Luca, A. Calarco, M. Finicelli, and G. Peluso, "Polyphenol-Loaded Nanodevices as Innovative Therapeutic Strategies for Dry Eye Disease: Advances and Perspectives," *Antioxidants*, vol. 14, no. 11, Multidisciplinary Digital Publishing Institute, p. 1280, Oct. 25, 2025. doi: 10.3390/antiox14111280.
24. S. Bhadra et al., "Reimagining ethnopharmacology with generative AI: Towards inclusive, ethical, and data-driven traditional medicine," *Pharmacological Research*, vol. 221, Elsevier BV, p. 108002, Oct. 19, 2025. doi: 10.1016/j.phrs.2025.108002.
25. N. Solanki, P. Mane, and V. Joshi, "An Ayurvedic perspective of Mutrashmari - Urinary Calculi along with Crystal Morphology," *Journal of Ayurveda and Integrated Medical Sciences*, vol. 10, no. 3, p. 407, May 2025, doi: 10.21760/jaims.10.3.63.
26. J. Gonzalez-Zapata et al., "A metric learning approach for endoscopic kidney stone identification," *Expert Systems with Applications*, vol. 255, p. 124711, Jul. 2024, doi: 10.1016/j.eswa.2024.124711.
27. S. R. Khan, B. K. Canales, and P. R. Dominguez-Gutierrez, "Randall's plaque and calcium oxalate stone formation: role for immunity and inflammation," *Nature Reviews Nephrology*, vol. 17, no. 6, p. 417, Jan. 2021, doi: 10.1038/s41581-020-00392-1.
28. V. A. N. Kátia et al., "Phyllanthin and hypophyllanthin determination by gas chromatography-mass spectrometry of six stonebreaker species from different regions of Brazil," *Journal of Medicinal Plants Research*, vol. 14, no. 4, p. 175, Apr. 2020, doi: 10.5897/jmpr2020.6909.
29. L. Soderberg et al., "Percutaneous nephrolithotomy versus retrograde intrarenal surgery for treatment of renal stones in adults," *Cochrane Database of Systematic Reviews*, vol. 2023, no. 12, Nov. 2023, doi: 10.1002/14651858.cd013445.pub2.
30. V. H. Canela et al., "A spatially anchored transcriptomic atlas of the human kidney papilla identifies significant immune injury in patients with stone disease," *Nature Communications*, vol. 14, no. 1, Jul. 2023, doi: 10.1038/s41467-023-38975-8.
31. R. S. Hsi, G. E. Tasian, and N. M. Maalouf, "Hydrochlorothiazide and Prevention of Kidney-Stone Recurrence," *New England Journal of Medicine*, vol. 388, no. 21, Massachusetts Medical Society, p. 2013,

- May 24, 2023. doi: 10.1056/nejmc2304100.
32. C. Noonin, A. Putpim, and V. Thongboonkerd, "The direct inhibitory effects of *Lactobacillus acidophilus*, a commensal urinary bacterium, on calcium oxalate stone development," *Microbiome*, vol. 12, no. 1, p. 175, Sep. 2024, doi: 10.1186/s40168-024-01877-y.
33. S. Ai et al., "Collision of herbal medicine and nanotechnology: a bibliometric analysis of herbal nanoparticles from 2004 to 2023," *Journal of Nanobiotechnology*, vol. 22, no. 1, Apr. 2024, doi: 10.1186/s12951-024-02426-3.
34. A. Setia, B. Vallamkonda, R. R. Challa, A. K. Mehata, P. Badgujar, and M. S. Muthu, "Herbal Theranostics: Controlled, Targeted Delivery and Imaging of Herbal Molecules," *Nanotheranostics*, vol. 8, no. 3, Ivyspring International Publisher, p. 344, Jan. 01, 2024. doi: 10.7150/ntno.94987.
35. G. I. Edo et al., "Eco-friendly nanoparticle phytosynthesis via plant extracts: Mechanistic insights, recent advances, and multifaceted uses," *Nano TransMed*, vol. 4, p. 100080, Mar. 2025, doi: 10.1016/j.ntm.2025.100080.
36. S. Das et al., "Regenerating rural soil and ecosystems: A 15-year systematic review of emerging methods and technologies," *The Science of The Total Environment*, vol. 990, Elsevier BV, p. 179926, Jun. 18, 2025. doi: 10.1016/j.scitotenv.2025.179926.
37. K. F. Al et al., "Multi-site microbiota alteration is a hallmark of kidney stone formation," *Microbiome*, vol. 11, no. 1, Nov. 2023, doi: 10.1186/s40168-023-01703-x.
38. L. Du et al., "Hyperuricemia and its related diseases: mechanisms and advances in therapy," *Signal Transduction and Targeted Therapy*, vol. 9, no. 1, p. 212, Aug. 2024, doi: 10.1038/s41392-024-01916-y.
39. S. Elayaperumal, Y. Sivamani, P. N. Agarwal, and N. Srivastava, "Plant-based nanotherapeutics: A new frontier in disease management and prevention," *Nano TransMed*, vol. 4, p. 100086, May 2025, doi: 10.1016/j.ntm.2025.100086.
40. E. Connelly, C. Lee, J. Furer-Pardoe, C. I. del Genio, and F. Harrison, "A case study of the Ancientbiotics collaboration," *Patterns*, vol. 3, no. 12, Elsevier BV, p. 100632, Dec. 01, 2022. doi: 10.1016/j.patter.2022.100632.
41. M. Kamath and V. Pai, "A PARADIGM OF RESEARCH IN AYURVEDA: BARRIERS AND OPPORTUNITIES," *International Research Journal of Pharmacy*, vol. 11, no. 5, p. 18, Jun. 2020, doi: 10.7897/2230-8407.110547.
42. A. Pujol, P. Sanchís, F. Grases, and L. Masmiquel, "Phytate Intake, Health and Disease: 'Let Thy Food Be Thy Medicine and Medicine Be Thy Food,'" *Antioxidants*, vol. 12, no. 1, p. 146, Jan. 2023, doi: 10.3390/antiox12010146.
43. F. Shan, L. Liu, L. Li, W. Y. R. Wang, Y. Bi, and M. Li, "Management, Safety, and Efficacy Evaluation of Nutraceutical and Functional Food: A Global Perspective," *Comprehensive Reviews in Food Science and Food Safety*, vol. 24, no. 4, Jul. 2025, doi: 10.1111/1541-4337.70222.
44. M. A. Eruaga, "THE ROLE OF REGULATORY AUTHORITIES IN THE REGULATION AND CONTROL OF HERBAL MEDICINES: A CASE STUDY OF NAFDAC," *International Medical Science Research Journal*, vol. 4, no. 3, p. 259, Mar. 2024, doi: 10.51594/imsrj.v4i3.917.
45. S. K. Keshari, A. Kumar, N. Gupta, D. N. Singh, and J. S. Prasad, "An etiopathological study of Mootra-Ashmari with special reference to Urolithiasis: A Literary Review," *Journal of Ayurveda and Integrated Medical Sciences*, vol. 9, no. 6, p. 184, Aug. 2024, doi: 10.21760/jaims.9.6.28.
46. K. D. Sanap and B. Gadve, "Ayurvedic management of renal calculus: A review article," Jan. 01, 2024. doi: 10.22271/phyto.2024.v13.i1b.14839.
47. Dr. D. Kanani, R. K. Sharma, V. Sangani, and A. Varsadiya, "A Classical Ayurveda and Modern Review of Mutrashmari S.R.Urolithiasis," *Asian Journal of Pharmaceutical Research and Development*, vol. 12, no. 2, p. 125, Apr. 2024, doi: 10.22270/ajprd.v12i2.1376.
48. N. Solanki, P. Mane, and V. Joshi, "An Ayurvedic perspective of Mutrashmari - Urinary Calculi along with Crystal Morphology," *Journal of Ayurveda and Integrated Medical Sciences*, vol. 10, no. 3, p. 407, May 2025, doi: 10.21760/jaims.10.3.63.
49. S. Pandya, C. Savaliya, and M. Lokhande, "Therapeutic Potential of Plant-Based Supplement as Adjunctive Treatment in Nephrolithiasis," Dec. 2024, doi: 10.52403/ijhsr.20241208.
50. B. Rath, P. Chaudhary, R. Rath, N. Lamba, and M. Khan, "Improvement in the

- Outcome of Urolithiasis Medicine Section Patients using Traditional Indian Medicine: A Systematic Review and Meta-analysis," Jan. 2024, doi: 10.7860/jcdr/2024/67928.19524.
51. K. Gurjar, "A Clinical Study to Evaluate Efficacy of Cap Ashma: 6 Hypothetical and Varunadi Kashya in the Management of Mootra Ashmari w.s.r.to Urolithiasis: A Research Article," *International Journal for Research in Applied Science and Engineering Technology*, vol. 10, no. 5, p. 3865, May 2022, doi: 10.22214/ijraset.2022.43250.
52. A. E. Allam *et al.*, "A holistic guide to effective prevention and treatment for kidney stones: a systematic review exploring anti-urolithiasis approaches," *Naunyn-Schmiedeberg's Archives of Pharmacology*. Springer Science+Business Media, Oct. 20, 2025. doi: 10.1007/s00210-025-04658-y.
53. V. Thongboonkerd, T. Yasui, and S. R. Khan, "Editorial: Immunity and Inflammatory Response in Kidney Stone Disease," *Frontiers in Immunology*, vol. 12, Nov. 2021, doi: 10.3389/fimmu.2021.795559.
54. F. Pinipay, R. Rokkam, B. Satyanarayana, and R. R. Tamanam, "Metabolomic and network Pharmacology insights into the anti-inflammatory and anti-urolithiatic potential of *Ficus religiosa* seeds," *Scientific Reports*, vol. 15, no. 1, p. 39098, Nov. 2025, doi: 10.1038/s41598-025-26906-0.
55. F. Liang, F. Guo, R. Liu, and X. Wang, "Research progress on the mechanisms of interleukin and chemokine families in driving calcium oxalate nephrolithiasis formation," *Frontiers in Immunology*, vol. 16. Frontiers Media, Sep. 12, 2025. doi: 10.3389/fimmu.2025.1651003.
56. H. Zhang, L. Klareskog, A. Matussek, S. M. Pfister, and M. Benson, "Translating genomic medicine to the clinic: challenges and opportunities," *Genome Medicine*, vol. 11, no. 1. BioMed Central, Feb. 22, 2019. doi: 10.1186/s13073-019-0622-1.
57. K. Dev, G. Gill, C. R. Yadav, and B. Singh, "Management of Renal Calculus through Ayurveda: A Case Report," *International Research Journal of Ayurveda & Yoga*, vol. 7, no. 1, p. 60, Jan. 2024, doi: 10.48165/irjay.2024.70110.
58. R. Kumar, "Ureteric Calculi in a 24 Year Old Man: A Case Study," *International Journal for Research in Applied Science and Engineering Technology*, vol. 12, no. 4, p. 5944, Apr. 2024, doi: 10.22214/ijraset.2024.58311.
59. Dr. Y. D. Madgulwar, B. Kalpana, Dr. K. J. Shewalkar, and B. Kalpana, "Pharmacokinetics and Pharmacodynamics: An Ayurvedic Perspective," May 2024, doi: 10.35629/4494-090510271037.
60. N. Stepanova, "Balancing Stone Prevention and Kidney Function: A Therapeutic Dilemma," *Journal of Clinical Medicine*, vol. 14, no. 11, p. 3678, May 2025, doi: 10.3390/jcm14113678.
61. W. Quan, Q. Li, H. Zhou, B. Su, Y. Ren, and Q. He, "Dysregulated lipid metabolism in kidney stone pathogenesis: a literature review of mechanistic insights and therapeutic implications," *BMC Urology*, vol. 25, no. 1. BioMed Central, Aug. 18, 2025. doi: 10.1186/s12894-025-01870-z.
62. A. T. Devi, R. Nagaraj, A. Prasad, D. B. Lakkappa, F. Zameer, and N. P. M. Nagalingaswamy, "Nephrolithiasis: Insights into Biomimics, Pathogenesis, and Pharmacology," *Clinical Complementary Medicine and Pharmacology*, vol. 3, no. 2, p. 100077, Dec. 2022, doi: 10.1016/j.ccmp.2022.100077.
63. M. Mukerji, "Ayurgenomics-based frameworks in precision and integrative medicine: Translational opportunities," *Cambridge Prisms Precision Medicine*, vol. 1. Cambridge University Press, Jan. 01, 2023. doi: 10.1017/pcm.2023.15.
64. K. Swathi and S. Sumathi, "Ayurveda and Transdisciplinary Approaches: A Way Forward towards Personalized and Preventive Medicine," *Indian Journal of Pharmaceutical Sciences*, vol. 85, no. 6, Jan. 2023, doi: 10.36468/pharmaceutical-sciences.1211.
65. S. P. Thyagarajan, "Integration of Ayush within national health care systems," *Journal of Research in Ayurvedic Sciences*, vol. 7, no. 1, p. 59, Jan. 2023, doi: 10.4103/jras.jras_166_22.